The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
Official Title: A PHASE 1 STUDY OF PF-05082566 AS A SINGLE AGENT IN PATIENTS WITH ADVANCED CANCER, AND IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA (NHL)
Study ID: NCT01307267
Brief Summary: A study of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb), in patients with solid tumors or b-cell lymphomas, and in combination with rituximab in patients with CD20 positive Non-Hodgkin's Lymphoma (NHL).
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
City of Hope, Duarte, California, United States
UC San Diego Moores Cancer Center-Investigational Drug Services, La Jolla, California, United States
UC San Diego Medical Center-La Jolla (Jacobs Medical Center/Thornton Hospital), La Jolla, California, United States
UC San Diego Moores Cancer Center, La Jolla, California, United States
Research Administration Office: Clinical Research Unit, Los Angeles, California, United States
Ronald Reagan UCLA Medical Center, Drug Information Center, Los Angeles, California, United States
UCLA Bowyer Clinic, Los Angeles, California, United States
UCLA Hematology-Oncology Clinic, Los Angeles, California, United States
Stanford University Medical Center, Palo Alto, California, United States
Stanford University Medical Center, Palo Alto, California, United States
UC San Diego Medical Center - Hillcrest, San Diego, California, United States
Santa Monica UCLA Hematology & Oncology Clinic, Santa Monica, California, United States
Stanford University Medical Center, Stanford, California, United States
Georgetown University Medical Center Department of Pharmacy, Research, Washington, District of Columbia, United States
MedStar Georgetown University Hospital, Washington, District of Columbia, United States
Emory University Hospital Midtown, Atlanta, Georgia, United States
Emory University Hospital, Atlanta, Georgia, United States
The Emory Clinic, Building A, Atlanta, Georgia, United States
The Emory Clinic, Atlanta, Georgia, United States
Winship Cancer Institute, Atlanta, Georgia, United States
Brigham and Woman's Hospital, Boston, Massachusetts, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
University of Michigan Health System, Ann Arbor, Michigan, United States
Siteman Cancer Center-West County, Creve Coeur, Missouri, United States
Barnes-Jewish Hospital, Saint Louis, Missouri, United States
Barnes-Jewish Hospital, Saint Louis, Missouri, United States
Washington University Infusion Center Pharmacy, Saint Louis, Missouri, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
Siteman Cancer Center- South County, Saint Louis, Missouri, United States
Siteman Cancer Center - St. Peters, Saint Peters, Missouri, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
The University of Texas - M.D. Anderson Cancer Center, Houston, Texas, United States
South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
Seattle Cancer Care Alliance, Seattle, Washington, United States
University of Washington Medical Center, Seattle, Washington, United States
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Centre d'investigation clinique, RENNES cedex 9, , France
Az. Ospedaliera-Univer. di Bologna Policlinico S. Orsola Malpighi, Bologna, BO, Italy
Ospedale San Raffaele di Milano, Milano, MI, Italy
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
Akita University Hospital, Akita, , Japan
The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, , Japan
Name: Pfizer CT.gov Call Center
Affiliation: Pfizer
Role: STUDY_DIRECTOR